Analysts have been eager to weigh in on the Healthcare sector with new ratings on Neurocrine (NBIX – Research Report), Day One Biopharmaceuticals (DAWN – Research Report) and Roche Holding AG (RHHVF – Research Report).
Neurocrine (NBIX)
In a report released today, Jay Olson from Oppenheimer maintained a Buy rating on Neurocrine, with a price target of $200.00. The company’s shares closed last Tuesday at $140.09, close to its 52-week high of $148.37.
According to TipRanks.com, Olson is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Neurocrine with a $153.81 average price target, implying a 9.1% upside from current levels. In a report issued on April 11, Stifel Nicolaus also maintained a Buy rating on the stock with a $165.00 price target.
See today’s best-performing stocks on TipRanks >>
Day One Biopharmaceuticals (DAWN)
Oppenheimer analyst Matthew Biegler maintained a Hold rating on Day One Biopharmaceuticals today. The company’s shares closed last Tuesday at $16.64, close to its 52-week high of $17.85.
According to TipRanks.com, Biegler is a 1-star analyst with an average return of
Day One Biopharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $35.67.
Roche Holding AG (RHHVF)
In a report released today, Emily Field from Barclays maintained a Hold rating on Roche Holding AG, with a price target of CHF250.00. The company’s shares closed last Tuesday at $250.79, close to its 52-week low of $236.98.
According to TipRanks.com, Field is ranked #5181 out of 8794 analysts.
Currently, the analyst consensus on Roche Holding AG is a Hold with an average price target of $270.59, representing a 9.0% upside. In a report issued on April 9, UBS also maintained a Hold rating on the stock with a CHF248.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on NBIX:
- Neurocrine’s NBI-1065845 shows efficacy in major depressive disorder
- Neurocrine, Sentia Medical Sciences extend CRF research collaboration
- Voyager announces selection of development candidate for GBA1 Program
- Neurocrine initiates Phase 1 study of NBI-1065890
- Neurocrine price target raised to $158 from $148 at JPMorgan
